Effect of Methotrexate Therapy on Visual Functions

Memona Mohiuddin | Muhammad Sharjeel | Zeeshan Hameed

ABSTRACT:
Aim: To find the effect of Methotrexate therapy on visual functions (visual acuity, contrast sensitivity, color vision, glare sensitivity, visual field) and ocular adnexa.

Study Design: Descriptive cross-sectional study

Place and Duration: College of Ophthalmology and Allied Vision Sciences (COAVS), Mayo Hospital Lahore from September 2016 to November 2016.

Material and Methods: A total of 30 patients having psoriasis and rheumatoid arthritis taking Methotrexate therapy with different doses and different durations were questioned through a specified Performa and then examined for changes in ocular adnexa and visual functions. Results were saved on Excel Sheets and analyzed with SPSS v.25.0.

Results: Patients taking Methotrexate therapy were found to have affected visual functions with color vision and visual field being more affected as compared to other visual functions. Dosage significantly affects color vision (p=.002) and visual field (p=.001). While in terms of duration, it was analyzed that there is significant relation (p=.006) between duration and the color vision and same was with the visual field (p=.001).

Conclusion: Methotrexate therapy has less effect on visual acuity, contrast sensitivity, glare sensitivity and ocular adnexa. However, color vision and visual field were affected due to Methotrexate therapy, and neurological visual field defects occur due to long term (1-2 years) therapy.

KEYWORDS
INTRODUCTION

Methotrexate (MTX) is an antimetabolite and antifolate drug widely used in treatment of psoriasis, rheumatoid arthritis, psoriatic arthritis, autoimmune diseases and for the initiation and maintenance of abatement in Crohn’s disease.\(^1\)\(^-\)\(^4\) It can be given as monotherapy or in combination with other drugs made up of oral agents and newer biological agents. Methotrexate is also effective in the treatment of malignant and non-malignant inflammatory diseases.\(^5\) It is prescribed as a first line treatment in active rheumatoid patients.\(^6\) It can be given orally or an injectable form.\(^7\) However, it also plays a major role in the therapy of cancer, ectopic pregnancy and for induction of medical abortion.\(^8\)\(^,\)\(^9\) Certain side effects of Methotrexate are hepatotoxicity, ulcerative stomatitis, neurologic damage and low white blood cell count and thus leading to infection, nausea, abdominal pain, fatigue, fever, dizziness, acute pneumonitis, rarely pulmonary fibrosis and kidney failure while most common side effects are gastrointestinal upset, oral ulceration and neutropenia.\(^10\) When this drug crosses blood brain barrier and damage neurons in cerebral cortex, neurotoxicity occurs. When MTX is administered in high doses, it also causes cutaneous and lung toxicity.\(^11\) It has an injurious effect on memory loss. To a great concern, it also causes potential visual and sight threatening complications.\(^12\)

Ocular toxicities caused by Methotrexate include periorbital edema, ocular pain, blurred vision, photophobia, conjunctivitis, blepharitis, decreased reflex tear secretion and Non-arteritic ischemic optic neuropathy. Optic neuropathy occurs due to folate deficiency that may be nutritional or genetic.\(^13\) Central scotoma with an unremarkable optic disc and toxic optic neuropathy is also found after long-term treatment with methotrexate.\(^14\) Cotton wool spots are also documented as the presenting feature of systemic MTX toxicity.\(^15\) Methotrexate when administered intravenously causes conjunctivitis, blurred vision and periorbital edema at high doses and when administered intrathecal causes inter-nuclear ophthalmoplegia. Isolated sixth nerve palsy is also included in an atypical complication of this drug.\(^16\) Neuro-ophthalmic toxicities such as optic nerve demyelization, optic neuropathy, retinal pigmentary mottling, myelopathy and aseptic meningitis occur due to the high doses of Methotrexate when given through intrathecal route.\(^17\)\(^,\)\(^18\) Ocular complications could be treated or prevented, if detected or diagnosed on time. Therefore, a basic ophthalmic examination for patients receiving Methotrexate therapy should be done to get early diagnosis regarding any ocular issue. For the assessment of ocular health, we can assess visual functions.

1.1 | Aims & Objectives

1. To detect the detrimental fluctuations occurring in visual functions in patients receiving Methotrexate therapy and correlate these fluctuations with dosage and duration.
2. To aware the public if potential sight-threatening complications of Methotrexate found.

2 | MATERIAL AND METHODS

2.1 | Research Design

It was a descriptive cross-sectional study.

2.2 | Population & Sampling

The study was conducted at College of Ophthalmology and Allied Vision Sciences (COAVS), Mayo Hospital Lahore from September 2016 to November 2016.

2.3 | Data Collection

All patients taking MTX therapy from 3 months to 2 years were included while patients having any other systemic disease contributing to visual dysfunction were excluded. The tools used for assessing visual functions were Log
Marchart for recording vision, Pelli Robson chart for contrast sensitivity, Farnsworth D15 chart for color vision, Humphrey automated visual field analyzer for recording visual field and slit lamp microscopy was used for assessment of ocular adnexa. Data was collected through a self-designed Performa. 30 patients were examined in the COAVS, Mayo Hospital. The patients using MTX were taken from the Orthopedics and Dermatology ward and examined in Eye ward Mayo hospital Lahore. Firstly, the consent was taken and all the tests were explained to the patient. Then the patients were clinically examined.

2.4 Analysis Technique

Data was analyzed in SPSS version 25.0. Non probability purposive sampling method was used. Different tables were made to represent the frequencies and relation between (Dosage, Duration) and visual functions.

3 RESULTS

30 patients were included in this study having age range between 18 years to 70 years with mean age of 36.70±12.14 years. There were 50% patients who received 5mg dosage, 38.67% patients with 2.5mg and 6.667% patients with 2ml and 5ml dosage in this study. 40% patients were taking therapy from 1.5 to 2 years, 36.67% patients from 0.5-1 year, and 23.33% patients from 0.5-1 year, and 23.33% patients from 2-3 months duration. Firstly, the relation between dosage and visual functions (visual acuity, contrast sensitivity, color vision, glare sensitivity, visual field) and ocular adnexa was seen in which there was no statistically significant difference between dosage and visual functions and adnexa. But color vision and visual fields were found to be affected by dosage as shown in tables below.

<table>
<thead>
<tr>
<th>TABLE 1 Dose vs. Color Vision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>Protane</td>
</tr>
<tr>
<td>Deutane</td>
</tr>
<tr>
<td>Tritane</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

FIGURE 1: Distribution of Age

FIGURE 2: Distribution of Dosage
Table # 1 shows that the majority of patients have Protane, Deutane and Tritane defects and few of the patients have normal color vision. As far as dosage concerns, 2.5 and 5 mg dosage affects color vision in more patients as compare to other dosages. However, the difference is statistically significant, One Way analysis of variances (ANOVA) F (2, 27) = 8.241 with a P value of .002 which is < 0.05 meaning that there is marked difference between dosages of Methotrexate therapy and color vision.

**Table 2** Dose vs. Visual Fields

<table>
<thead>
<tr>
<th>Dosage</th>
<th>2.5 mg</th>
<th>5 mg</th>
<th>2 ml</th>
<th>5 ml</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual field</td>
<td>Affected</td>
<td>4</td>
<td>12</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Not affected</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>11</td>
<td>15</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Table # 2 shows that the majority of patients have affected visual field taking 2.5 and 5 mg dosage. However, the difference is statistically significant, One Way analysis of variances (ANOVA) F (2, 27) = 21.441 with a P value of .001 which is < 0.05 meaning that there is marked difference between dosages of Methotrexate therapy and visual field. Secondly, the relationship between duration and visual functions was seen in which there was no statistically significant difference between duration and (visual acuity, contrast sensitivity, glare sensitivity), adnexa. But color vision and visual field were found to be affected by increasing duration i.e. shown in the tables below.

**Table 3** Duration Vs Color Vision

<table>
<thead>
<tr>
<th>Variable</th>
<th>Category</th>
<th>Duration</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2-3 months</td>
<td>0.5-1.0 year</td>
</tr>
<tr>
<td>Color Vision</td>
<td>Normal</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Protane</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Deutane</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Tritane</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>7</td>
<td>11</td>
</tr>
</tbody>
</table>

Table # 3 shows that the majority of patients have color vision defect taking therapy from 1-2 years as compare to patients taking therapy from 2-3 months. The Pearson Chi square value is 18.015 at degree of freedom 6, giving the p value of .006 which means that there is statistically significant relationship between duration and color vision.

Table # 4 shows that visual field is affected in patients taking therapy from 1-2 year. As a whole majority of patients have affected visual field and minority of patients have not affected visual field. The Pearson Chi square value is
18.409 at degree of freedom 2, giving the p value of .001 which means that there is statistically significant relationship between duration and visual field.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Category</th>
<th>Duration 2-3 months</th>
<th>0.5-1.0 year</th>
<th>1.5-2.0 year</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual field</td>
<td>Affected</td>
<td>0</td>
<td>10</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Not Affected</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>7</td>
<td>11</td>
<td>12</td>
<td>30</td>
</tr>
</tbody>
</table>

4 | DISCUSSION

Numerous systemic drugs produce adverse effects that involve the eye. The eye because of its rich blood supply and relatively small mass exhibits an unusually high susceptibility to toxic substances. Drug molecules present in systemic circulation can reach the ocular structures by way of the uveal or retinal vasculature. The clinicians all over the globe are agreed about the side effects of drugs on the eye. Many of the drugs have adverse effects on the body organs in the same way they can also affect the eye. So this is essential to accurately evaluate visual functions as this will help in early diagnosis of conditions and also monitor the diseases like glaucoma, cataract etc. As with other drugs, Methotrexate is not without ocular side effects. Balachandran C and his colleagues did a study to evaluate the adverse effects of Methotrexate on the eye. In this study it was seen that Methotrexate inhibits folate metabolism that results in folate defalcation which leads to optic neuropathy. Methotrexate induced optic neuropathy involves pathogenesis of demyelinating optic neuropathy. So in this study, Toxic optic neuropathy caused by Methotrexate was observed.

Another study in which a female patient suffering from psoriatic arthritis was given Methotrexate therapy for a long time. The acute attack of the central visual field defect occurs in her right eye that gets worse within one year. When the MTX therapy was stopped, after six weeks her visual field defects started improving. It was concluded that long term treatment with MTX can result in unilateral central visual field defect in a patient taking MTX therapy even with folic acid supplement. This was also proposed by Adhikari et al. in their study done on CNS lymphoma treated with methotrexate.

In the present study patients taking Methotrexate therapy were found to have affected visual function. This was observed that a large number of patients have Protane, Deutane and Tritane color vision deficiencies. 2.5 and 5 mg dosage affects color vision in more patients as compared to other dosages. So, Dosage of Methotrexate therapy significantly affects (p = 0.002) color vision causing Protagopia, Deutanopia and Tritanopia. Clare et al. also described similar patterns of defective color vision in patients taking 2.5mg dosage 3 times a week. In the same way, the visual field is also affected significantly (p=0.001) by the (2.5 and 5 mg) dosage of Methotrexate therapy. Although 17(56.7%) patients have defective glare sensitivity but in terms of dosage, there was no statistically significant relationship between dosage and Methotrexate therapy. As far as the duration is concerned, therapy taken for 1-2 years has more effects as compared to therapy taken from 2-3 months. So in terms of duration, Methotrexate therapy significantly affects (p=.006) color vision and visual field (p=.001). It was concluded that as compared to the other visual functions color vision and visual field were affected more. This was also supported by Zahar et al. in his work. Patients show scotomas and visual field defects (neurological) due to long term (1-2 year) use of Methotrexate therapy.

There’s very limited data showing that Methotrexate causes color vision defects. As in other studies showing visual field defects with Methotrexate, our study also reveals a strong association between visual field defects and Methotrexate therapy. However, there was no statistically significant association between (dosage & duration) of
Methotrexate therapy and visual status, contrast sensitivity, glare sensitivity and adnexa.

5 | LIMITATIONS AND FUTURE DIRECTIONS

This study’s main limitation is small sample size and even smaller duration. To have a greater future impact, a vast multicenter study with more sample size needs to be conducted. Moreover, only subjective aspects of visual functions were assessed in this study, ignoring objective findings like fundus examination and other clinical tests of optic nerve function. This needs to be addressed in future works. However, despite its limitations, this study might prove to be a guide for physicians prescribing MTX to keep an eye on ocular side effects of the drug during its course of prescription and timely referral to ophthalmologist for subsequent management.

6 | CONCLUSION

Methotrexate is a drug known to cause visual function deterioration in the long term but our paper further elaborated that which functions are more affected and which are less affected. It was concluded that as compared to other visual functions (visual status, contrast sensitivity, glare sensitivity and adnexa) color vision and visual field were affected due to Methotrexate therapy. This study shows more deleterious effects on visual field and color vision with 1-2 years’ duration and (2.5mg, 5mg) dosage.

Ethical Approval
No ethical approval was needed for this study.

Conflict of Interests
None declared.

Funding
None

REFERENCES